About us - BIONNA (Beijing) Medicine Co., Ltd.

Company Profile

Company profile

BIONNA

BIONNA (Beijing) Medicine Co., Ltd. is a research and development (R&D)-driven enterprise that applies the concept of "Quality by Design (QbD)" to all aspects of drug R&D, and has created a pharmaceutical C&MC development platform, a pharmaceutical crystallization/powder engineering platform, and a suspension process development platform; based on the enterprise's technical platform, it has completed the development of multiple drug substances for inhalation preparations and complex preparations, and determined the crystallization process or powder properties of different products. From the preparation of gram-grade compounds to the commercial production of active substances, we can undertake CRO/CDMO/CMO business at different stages. At present, the self-developed products have covered respiratory, antiviral, antitumor and other fields.

Development History

history

2016

In 2016, BIONNA (Beijing) Medicine was established and a R&D team was created

2017

In 2017, the C&MC platform was built, the API R&D of inhalation preparation was carried out, and the CRO business was arranged

2018

In 2018, China’s first-class pharmaceutical powder engineering platform was built

2019

In 2019, the process development, quality study and pilot scale-up of API of multiple inhalation preparations were completed; meanwhile, we established cooperation with domestic and foreign inhalation preparation enterprises

2020

In 2020, pre-A round of financing was completed, with BIONNA Medicine (688166. SH) as the lead investor, and Breathgreen (Shandong) Pharmaceutical Co., Ltd. was established

2021

In 2021, the construction and trial operation of the cGMP plant covering an area of 40 mu was completed; and the company was awarded the National High Tech Enterprise, Deloitte-Yizhuang High-tech High-growth Top 20

2022

In 2022, the drug substance products of inhalation preparations were transferred and registered for production in the cGMP plant, and the drug production license was obtained; CDMO business was started; the founder was awarded “Yiqilin” talents of Beijing Economic and Technological Development Zone

2016

2017

2018

2019

2020

2021

2022

Founding Team

team

Kun Yin/ President

Worked at General Electric (GE) in the United States and Weidmuller in Germany

Bachelor Degree in Industrial Automation, North China Electric Power University

EMBA, Guanghua School of Management, Peking University

Hao Li, Ph.D./ General Manager

Former Pharmaceutical Chemistry Scientist, Forma Therapeutics, Singapore

Former Senior Scientist, Pharmaceutical Chemistry, AMRI, Singapore

Former Senior Process Research Scientist, GlaxoSmithKline, Singapore

PhD, Nanyang Technological University, Singapore

Kiewching Lee, Ph.D./ Chief Scientist Officer

Former Chief Scientist Officer, GlaxoSmithKline Centre for Central Nervous Drug Development

Former GlaxoSmithKline Directing Professor of Industry: University of Edinburgh, UK (MSc), Monash University, Australia (PhD), University of Montpellier 1, France (MSc)

PhD, National University of Singapore

Baoli Cai/ Vice General Manager

Director of Generic Drug Development & Director of Drug Substance Technology Transfer

Bachelor of Pharmaceutical Engineering, Hebei University of Technology/Master of Organic Chemistry, Nankai University

Over 12 years of factory scale-up experience with more than 50 projects